Piperacillin/Tazobactam vs Imipenem/Cilastatin in the Treatment of Nosocomial Pneumonia—a Double Blind Prospective Multicentre Study

@article{Schmitt2006PiperacillinTazobactamVI,
  title={Piperacillin/Tazobactam vs Imipenem/Cilastatin in the Treatment of Nosocomial Pneumonia—a Double Blind Prospective Multicentre Study},
  author={D. V. Schmitt and Eva Leitner and Tobias Welte and Hartmut Lode},
  journal={Infection},
  year={2006},
  volume={34},
  pages={127-134}
}
Background:Piperacillin/tazobactam (P/T) with its broad spectrum of antibacterial activity is used widely for the treatment of moderate to severe polymicrobial nosocomial infections.Patients and Methods:The efficacy and safety of P/T was compared with imipenem/cilastatin (I/C) in patients with established nosocomial pneumonia. This multicentre study took place from January 1999 to December 2001. Due to difficulties in recruiting sufficient patients it was terminated prematurely. In all, 221… 

Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study*

TLDR
Doripenem was clinically and microbiologically effective in patents with NP, including those with early-onset ventilator-associated pneumonia, and was therapeutically noninferior to piperacillin/tazobactam.

Efficacy and safety of piperacillin/tazobactam versus imipenem/cilastatin therapy for pneumonia: a meta-analysis of randomized controlled trials

TLDR
This meta-analysis provides that piperacillin/tazobactam can be used as safe and efficacious as imipenem/cilastatin in treating hospitalized patients with pneumonia.

Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review

TLDR
In the 15 years of RCTs of imipenem for pneumonia, PA imiponem resistance rates are high, and PA clinical success and microbiologic eradication rates are directionally lower for imipanem than for comparators; Conversely, initial and treatment-emergent resistance is more likely with the imIPenem than the comparator regimens.

Efficacy and safety of piperacillin/tazobactam versus biapenem in late elderly patients with nursing- and healthcare-associated pneumonia

  • F. KarinoKiyotaka Miura T. Isobe
  • Medicine, Biology
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
  • 2013
TLDR
Providing careful follow-up and conducting more detailed examinations, including studies to determine optimal dose and timing of administration, are necessary for the treatment of late elderly patients with numerous underlying diseases and potential organ dysfunctions.

Carbapenems versus other beta-lactams in the treatment of hospitalised patients with infection: a mixed treatment comparison

TLDR
This mixed treatment comparison suggests meropenem has substantial advantages over cefepime, ertapenem, imipenem/cilastatin and piperacillin/tazobactam in the treatment of hospitalised patients with infection.

Carbapenems versus other beta-lactams in the treatment of hospitalised patients with infection: a mixed treatment comparison.

TLDR
This mixed treatment comparison suggests meropenem has substantial advantages over cefepime, ertapenem, imipenem/cilastatin and piperacillin/tazobactam in the treatment of hospitalised patients with infection.

Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial

TLDR
The therapeutic advantage of early administration of broad-spectrum antimicrobials, especially with vancomycin, was not evident in this study and Multidrug-resistant organisms, especially MRSA, were more likely to emerge in the DE group.

Therapeutic equivalence of generic imipenem/cilastatin for therapy of infections at Siriraj Hospital.

TLDR
Although the point estimate of composite favorable outcome of the patients who received generic imipenem/cilastatin (Yungjin) was < 10% of those who received original imipeni/cilastsatin (Tienam), generic imipsine showed a trend for therapeutic non-equivalence to originalImipenm/cilASTatin because the upper limits of 95% confidence interval of differences of several important clinical outcomes were more than 10%.

Pharmacokinetic evaluation of piperacillin-tazobactam

TLDR
Alternative dosing regimens, which may include administration by extended or continuous infusion of piperacillin-tazobactam as a mechanism to increase the likelihood of pharmacodynamic target attainment, are described.

References

SHOWING 1-10 OF 29 REFERENCES

Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial

TLDR
Amikacin associated with either ceftazidime or piperacillin and tazobactam has shown comparable efficacy and tolerability in the treatment of ICU patients with nosocomial pneumonia.

Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. VAP Study Group.

TLDR
It is concluded that the two regimens were of equivalent clinical efficacy in therapy for confirmed VAP, and fewer bacteriologic failures occurred with TAZ than with CAZ.

Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam Nosocomial Pneumonia Study Group.

TLDR
Piperacillin/tazobactam plus tobramycin was shown to be more effective and as safe as ceftazidime plus tobramsycin in the treatment of patients with nosocomial LRTI.

Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia

TLDR
Piperacillin/tazobactam is safe and highly efficacious in the treatment of serious pneumonia in hospitalized patients and compares favorably with the combination of co-amoxiclav/aminoglycoside.

Prospective Randomized Comparison of Imipenem-Cilastatin and Piperacillin-Tazobactam in Nosocomial Pneumonia or Peritonitis

TLDR
This study suggests that piperacillin-tazobactam monotherapy is at least as effective and safe as imipenem-cilastatin monotherapy in the treatment of nosocomial pneumonia or peritonitis.

Piperacillin/tazobactam: a critical review of the evolving clinical literature.

  • W. SandersC. Sanders
  • Biology, Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1996
TLDR
Piperacillin/tazobactam may be especially useful for the treatment of infections that are likely to be polymicrobial or to be due to any one of an array of aerobic or anaerobic bacteria; this agent may also be useful in situations where organisms with plasmid-mediated beta-lactamases have become problematic.

Study of the comparative activity of piperacillin/tazobactam with currently available antibiotics against 8206 aerobic isolates.

TLDR
A broad spectrum of activity of piperacillin-tazobactam is confirmed and the pattern of susceptibility is quite uniform from different body sites, in both teaching and community hospitals, and across the country.

Treatment with a Broad-Spectrum Cephalosporin versus Piperacillin-Tazobactam and the Risk for Isolation of Broad-Spectrum Cephalosporin-Resistant Enterobacter Species

TLDR
The protective effect of fluoroquinolones against isolation of broad-spectrum cephalosporin-resistant Enterobacter spp.

A Practical Look at the Clinical Usefulness of the Beta-Lactam/Beta-Lactamase Inhibitor Combinations

TLDR
There are important differences among the available beta-lactam/beta- lactamase inhibitor combinations, such as spectra of activity, which need to be considered in choosing an agent for a patient-specific case.